KR20130096712A - 튜불리신을 제조하기 위한 방법 - Google Patents

튜불리신을 제조하기 위한 방법 Download PDF

Info

Publication number
KR20130096712A
KR20130096712A KR1020137004980A KR20137004980A KR20130096712A KR 20130096712 A KR20130096712 A KR 20130096712A KR 1020137004980 A KR1020137004980 A KR 1020137004980A KR 20137004980 A KR20137004980 A KR 20137004980A KR 20130096712 A KR20130096712 A KR 20130096712A
Authority
KR
South Korea
Prior art keywords
compound
formula
alkyl
optionally substituted
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137004980A
Other languages
English (en)
Korean (ko)
Inventor
이온초 라도슬라보브 블라호브
마이클 그론닝
폴 조셉 클라인들
하리 크리쉬나 알. 산트라푸람
페이 유
유 왕
레-쿤 유
캐서린 마리에 스탠포드
알렌 리터
크리스토퍼 폴 리아몬
Original Assignee
엔도사이트, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엔도사이트, 인코포레이티드 filed Critical 엔도사이트, 인코포레이티드
Publication of KR20130096712A publication Critical patent/KR20130096712A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020137004980A 2010-08-06 2011-08-05 튜불리신을 제조하기 위한 방법 Ceased KR20130096712A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37143310P 2010-08-06 2010-08-06
US61/371,433 2010-08-06
PCT/US2011/046797 WO2012019123A1 (en) 2010-08-06 2011-08-05 Processes for preparing tubulysins

Publications (1)

Publication Number Publication Date
KR20130096712A true KR20130096712A (ko) 2013-08-30

Family

ID=45559842

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137004980A Ceased KR20130096712A (ko) 2010-08-06 2011-08-05 튜불리신을 제조하기 위한 방법

Country Status (12)

Country Link
US (3) US8889880B2 (cg-RX-API-DMAC10.html)
EP (1) EP2600866A4 (cg-RX-API-DMAC10.html)
JP (1) JP2013535220A (cg-RX-API-DMAC10.html)
KR (1) KR20130096712A (cg-RX-API-DMAC10.html)
CN (1) CN103140227B (cg-RX-API-DMAC10.html)
AU (1) AU2011285532B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013003004A2 (cg-RX-API-DMAC10.html)
CA (1) CA2807511A1 (cg-RX-API-DMAC10.html)
EA (1) EA025471B1 (cg-RX-API-DMAC10.html)
MX (1) MX2013001402A (cg-RX-API-DMAC10.html)
SG (1) SG187728A1 (cg-RX-API-DMAC10.html)
WO (1) WO2012019123A1 (cg-RX-API-DMAC10.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101098854B (zh) 2004-07-23 2012-12-05 恩多塞特公司 二价连接体及其轭合物
US20100104626A1 (en) 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CN104127878A (zh) 2007-03-14 2014-11-05 恩多塞特公司 结合配体连接的微管溶素递药缀合物
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
BRPI0812970A2 (pt) 2007-06-25 2019-09-24 Endocyte Inc conjugados contendo espaçadores hidrofílicos
EP2209374B1 (en) 2007-10-25 2014-12-03 Endocyte, Inc. Tubulysins and processes for preparing
US8889880B2 (en) 2010-08-06 2014-11-18 Endocyte, Inc. Processes for preparing tubulysins
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US20140080175A1 (en) * 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
EA201590622A1 (ru) 2012-10-16 2015-10-30 Эндосайт, Инк. Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения
KR102318999B1 (ko) 2012-11-15 2021-10-29 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
US20140249315A1 (en) 2013-03-01 2014-09-04 Endocyte, Inc. Processes for preparing tubulysins
WO2015113760A1 (en) * 2014-01-28 2015-08-06 Tube Pharmaceuticals Gmbh Cytotoxic tubulysin compounds for conjugation
CA2943299A1 (en) 2014-04-11 2015-10-15 Medimmune, Llc Bispecific her2 antibodies
RU2715905C2 (ru) 2014-10-01 2020-03-04 МЕДИММЬЮН, ЭлЭлСи Способ конъюгации полипептида
KR20170137725A (ko) * 2015-02-25 2017-12-13 윌리엄 마쉬 라이스 유니버시티 데스아세톡시투불리신 h 및 이의 유사체
PL3374398T3 (pl) 2015-11-10 2020-08-24 Medimmune, Llc Cząsteczki wiążące swoiste dla ASCT2 i ich zastosowanie
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
RU2018128784A (ru) 2016-01-27 2020-02-27 МЕДИММЬЮН, ЭлЭлСи Способы получения антител с заданным профилем гликозилирования
CN109069633A (zh) 2016-04-15 2018-12-21 宏观基因有限公司 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法
AR111963A1 (es) 2017-05-26 2019-09-04 Univ California Método y moléculas
UA126813C2 (uk) 2017-08-01 2023-02-08 Медімм'Юн, Ллк Моноклональний кон’югат антитіло-лікарський засіб до bcma
US11274124B2 (en) 2017-11-29 2022-03-15 William Marsh Rice University Tubulysin analogues as anticancer agents and payloads for antibody-drug conjugates and methods of treatment therewith
CN116829592A (zh) 2020-09-11 2023-09-29 免疫医疗有限公司 治疗性b7-h4结合分子
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
KR20240099430A (ko) 2021-11-10 2024-06-28 아스트라제네카 아베 항체 분자 및 접합체
GB202117928D0 (en) 2021-12-11 2022-01-26 Cancer Research Tech Ltd Immunotherapy for cancer
KR20240159839A (ko) 2022-03-09 2024-11-06 아스트라제네카 아베 FRα에 대한 결합 분자
JP2025525410A (ja) 2022-06-27 2025-08-05 アストラゼネカ・アクチエボラーグ 癌を治療するための上皮成長因子受容体チロシンキナーゼ阻害剤を伴う組み合わせ
TW202448517A (zh) 2023-02-16 2024-12-16 瑞典商阿斯特捷利康公司 用治療性結合分子治療癌症的組合療法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
EP1521769B1 (de) 2002-07-09 2015-09-09 Dömling, Alexander Tubulysinkonjugate
US7816377B2 (en) 2002-07-09 2010-10-19 R&D-Biopharmaceuticals Gmbh Tubulysin analogues
DE10254439A1 (de) 2002-11-21 2004-06-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Tubulysine, Herstellungsverfahren und Tubulysin-Mittel
US7601332B2 (en) 2003-01-27 2009-10-13 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
CN104127878A (zh) 2007-03-14 2014-11-05 恩多塞特公司 结合配体连接的微管溶素递药缀合物
DE102009032972A1 (de) 2009-07-14 2011-01-20 Erbe Elektromedizin Gmbh Vorrichtung zur Herstellung von Anastomosen
WO2011069116A1 (en) 2009-12-04 2011-06-09 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
CA2790577A1 (en) 2010-02-25 2011-09-01 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US8889880B2 (en) * 2010-08-06 2014-11-18 Endocyte, Inc. Processes for preparing tubulysins

Also Published As

Publication number Publication date
US20160177363A1 (en) 2016-06-23
CA2807511A1 (en) 2012-02-09
AU2011285532B2 (en) 2015-09-10
US8889880B2 (en) 2014-11-18
EP2600866A4 (en) 2013-12-11
US9499849B2 (en) 2016-11-22
EA201390203A1 (ru) 2013-08-30
EA025471B1 (ru) 2016-12-30
JP2013535220A (ja) 2013-09-12
MX2013001402A (es) 2013-08-29
US20130137139A1 (en) 2013-05-30
US9273091B2 (en) 2016-03-01
HK1185558A1 (zh) 2014-02-21
WO2012019123A1 (en) 2012-02-09
CN103140227A (zh) 2013-06-05
CN103140227B (zh) 2016-01-20
EP2600866A1 (en) 2013-06-12
BR112013003004A2 (pt) 2016-06-14
AU2011285532A1 (en) 2013-02-21
SG187728A1 (en) 2013-03-28
US20150225447A1 (en) 2015-08-13

Similar Documents

Publication Publication Date Title
US9273091B2 (en) Processes for preparing tubulysins
EP2831059B1 (en) Processes for preparing tubulysin derivatives and conjugates thereof
US9771391B2 (en) Process for preparing tubulysins
Zhao et al. Modified taxols, 6. Preparation of water-soluble prodrugs of taxol
EP3676265B1 (en) Method for the synthesis of cyclic depsipeptides
EP0178980B1 (fr) Dérivés de céphalosporines, procédé d'obtention et leur application à titre d'antibiotiques
EP3512835A1 (en) A process for purification of carfilzomib intermediate
KR101331984B1 (ko) 카스포펀진 제조방법 및 그의 신규 중간체
HK1185558B (en) Processes for preparing tubulysins
AU2013203491A1 (en) Processes for preparing tubulysins
PT1487802E (pt) Derivados de 2,3-diaril-pirazolidina como inibidores sobre as enzimas que degradam a neurotensina neuropeptídica
US6274742B1 (en) Method for synthesis of N-homocysteine thiolactonyl retinamide
EP0832879A1 (en) Process for preparing intermediates for thrombin inhibitors
JP6235473B2 (ja) 大環状hcvプロテアーゼ阻害剤を製造するための方法および中間体
KR970004044B1 (ko) 약물동력학적으로 개선된 세팔로스포린 유도체, 그의 제조방법, 그를 함유하는 약제학적 조성물 및 합성 중간체
EP3480195A1 (en) Method for the synthesis of cyclic depsipeptides
JPH08109180A (ja) O→n分子内アシル転位型プロドラッグ
JPS621398B2 (cg-RX-API-DMAC10.html)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130227

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160802

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170628

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170926

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170628

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I